Arca
Skip to content
Tools
Tools

Label Changes: Crestor (rosuvastatin calcium)

A drug's label (its prescribing information) is revised many times after approval: new warnings, new uses, new doses. DailyMed keeps every version. Pick a drug to see them all and what changed between any two.

Every version of the Crestor label DailyMed has published, from AstraZeneca Pharmaceuticals LP, and what changed between any two of them, section by section. Current label on DailyMed.

  • Versions on DailyMed: 12
  • Sections changed, version 14 to 19: 10

What changed from version 14 to version 19

May 13, 2026 to Sep 30, 2026, as published on DailyMed. Added text is underlined in green, removed text struck through in red.
  1. Indications and usageChanged · 1 word added, 1 removed
  2. Dosage and administrationChanged · 8 words added, 6 removed
  3. Warnings and precautionsChanged · 29 words added, 50 removed
  4. Adverse reactionsChanged · 4 words added, 2 removed
  5. Drug interactionsChanged · 43 words added
  6. Use in specific populationsChanged · 1 word added, 1 removed
  7. Clinical pharmacologyChanged · 50 words added, 68 removed
  8. Clinical studiesChanged · 13 words added, 9 removed
  9. Patient counseling informationChanged · 2 words added, 1 removed
  10. Patient informationChanged · 549 words added, 528 removed

Indications and usage

Changed1 word added, 1 removed
1 unchanged line
CRESTOR is indicated:
• To reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction, nonfatal stroke, or an arterial revascularization procedure) in adults at increased risk for CVthese events.
• As an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C): ∘in adults with hypercholesterolemia. ∘and slow the progression of atherosclerosis in adults. ∘in adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH). ∘in adults and pediatric patients aged 7 years and older with homozygous familial hypercholesterolemia (HoFH).
1 unchanged line

Dosage and administration

Changed8 words added, 6 removed
28 unchanged lines
Darolutamide | Do not exceed 5 mg once daily.
Vadadustat | Do not exceed 5 mg once daily.
Additional Antiviral Medications
5 unchanged lines
Teriflunomide | Do not exceed 10 mg once daily.
Ticagrelor | Do not exceed 20 mg once daily. In patients at increased risk for rhabdomyolysis [see Warnings and Precautions (5.1) ], consider dosages less than 20 mg per day.
Febuxostat | Do not exceed 20 mg once daily.
1 unchanged line

Warnings and precautions

Changed29 words added, 50 removed
5 unchanged lines
Steps to Prevent or Reduce the Risk of Myopathy and Rhabdomyolysis
The concomitant use of CRESTOR with cyclosporine or gemfibrozil is not recommended. CRESTOR dosage modifications are recommended for patients taking certain antiviral medications, darolutamide, and regorafenib [see Dosage and Administration (2.6)]. Niacin, fibrates, and colchicine may also increase the risk of myopathy and rhabdomyolysis [see Drug Interactions (7.1)].
CRESTOR dosage modifications are recommended for patients taking certain medications; concomitant use with certain other medications should be avoided [see Dosage and Administration (2.6) , Drug Interactions (7.1) ] .
Discontinue CRESTOR if markedly elevated CK levels occur or if myopathy is either diagnosed or suspected. Muscle symptoms and CK elevations may resolve if CRESTOR is discontinued. Temporarily discontinue CRESTOR in patients experiencing an acute or serious condition at high risk of developing renal failure secondary to rhabdomyolysis (e.g., sepsis; shock; severe hypovolemia; major surgery; trauma; severe metabolic, endocrine, or electrolyte disorders; or uncontrolled epilepsy).
11 unchanged lines

Adverse reactions

Changed4 words added, 2 removed
30 unchanged lines
Table 4: Adverse Reactions Reported in ≥2% of Patients Treated with CRESTOR and > Placebo in the JUPITER Trial
Adverse Reactions | Placebo N=89018,901 % | CRESTOR 20 mg N=89018,901 %
Myalgia | 6.6 | 7.6
16 unchanged lines

Drug interactions

Changed43 words added
21 unchanged lines
Mechanism and Clinical Effect(s): | Darolutamide increased rosuvastatin exposure more than 5-fold. The risk of myopathy and rhabdomyolysis is increased with concomitant use.
Vadadustat
Prevention or Management: | In patients taking vadadustat, do not exceed a dosage of CRESTOR 5 mg once daily.
Mechanism and Clinical Effect(s): | Vadadustat increased rosuvastatin exposure by 2.5-fold. The risk of myopathy and rhabdomyolysis is increased with concomitant use.
Additional Anti-Viral Medications
47 unchanged lines

Use in specific populations

Changed1 word added, 1 removed
30 unchanged lines
8.7 Hepatic Impairment
CRESTOR is contraindicated in patients with acute liver failure or decompensated cirrhosis. Chronic alcohol liver disease is known to increase rosuvastatin exposure. Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury [see Contraindications (4), WarningWarnings and Precautions (5.3) and Clinical Pharmacology (12.3)].
8.8 Asian Patients
1 unchanged line

Clinical pharmacology

Changed50 words added, 68 removed
13 unchanged lines
Metabolism
Rosuvastatin is not extensively metabolized; approximately 10% of a radiolabeled dose is recovered as metabolite. The major metabolite is N-desmethyl rosuvastatin, which is formed principally by cytochrome P450 \/ 2C9, and in vitro studies have demonstrated that N-desmethyl rosuvastatin has approximately one-sixth to one-half the HMG‑CoA reductase inhibitory activity of the parent compound. Overall, greater than 90% of active plasma HMG‑CoA reductase inhibitory activity is accounted for by the parent compound.
Excretion
8 unchanged lines
Racial or Ethnic Groups
A population pharmacokinetic analysis revealed no clinically relevant differences in pharmacokinetics among White, Hispanic or Latino ethnicity, and Black or Afro-Caribbean groups. However, pharmacokinetic studies, including one conducted in the US, have demonstrated an approximate 2 -fold elevation in median exposure (AUC and Cmax) in Asian subjects when compared with a White control group.
Patients with Renal Impairment
4 unchanged lines
In patients with Child‑Pugh A disease, Cmax and AUC were increased by 60% and 5%, respectively, as compared with patients with normal liver function. In patients with Child‑Pugh B disease, Cmax and AUC were increased 100% and 21%, respectively, compared with patients with normal liver function.
Drug Interactions Studies
Drug Interaction Studies
Rosuvastatin clearance is not dependent on metabolism by cytochrome P450 3A4 to a clinically significant extent.
3 unchanged lines
| | Mean Ratio (ratio with/without coadministered drug) No Effect=1.0
| Dosage (mg) 1 | Change in AUC | Change in Cmax
Sofosbuvir/velpatasvir/voxilaprevir (400 mg/100 mg/100 mg) + Voxilaprevir (100 mg) once daily for 15 days | 10 mg, single dose | 7.39 (6.68 to 8.18) 3 | 18.88 (16.23 to 21.96) 3
Cyclosporine – stable dose required (75 mg – 200 mg BID) | 10 mg, QD for 10 days | 7.1 | 11
Darolutamide 600 mg BID, 5 days | 5 mg, single dose | 5.2 2 | ~5 2
Belumosudil 200 mg QD, 8 days | 10 mg, single dose on 2 separate days | 4.62 | 3.59
2 unchanged lines
Atazanavir/ritonavir combination 300 mg/100 mg QD for 8 days | 10 mg | 3.1 | 7
Simeprevir 150 mg QD, 7 days | 10 mg, single dose | 2.8 2 (2.3 to 3.4) 3 | 3.2 (2.6 to 3.9) 3
Momelotinib 200 mg OD, 5 days | 10 mg, single dose | 2.7 | 3.2
Velpatasvir 100 mg once daily | 10 mg, single dose | 2.69269 (2.46 to 2.94) 3 | 2.61 (2.32 to 2.92) 3
Ombitasvir 25 mg/paritaprevir 150 mg/ ritonavir 100 mg + dasabuvir 400 mg BID | 5 mg, single dose | 2.59 (2.09 to 3.21) 3 | 7.13 (5.11 to 9.96) 3
Teriflunomide | Not available | 2.51 | 2.65
Vadadustat 600 mg OD, 8 days | 20 mg, single dose on 2 separate days | 2.47 | 2.75
Ticagrelor 90 mg BID | 10 mg, single dose 20 mg, single dose | 2.3 2.3 | 2.4 2.6
Elbasvir 50 mg/grazoprevir 200 mg once daily | 10 mg, single dose | 2.26 (1.89 to 2.69) 3 | 5.49 (4.29 to 7.04) 3
Glecaprevir 400 mg/pibrentasvir 120 mg once daily | 5 mg, once daily | 2.15 (1.88 to 2.46) 3 | 5.62 (4.80 to 6.59) 3
Lopinavir/ritonavir combination 400 mg/100 mg BID for 17 days | 20 mg, QD for 7 days | 2.1 (1.7 to 2.6) 3 | 5 to (3.4 to6.4)
Capmatinib 400 mg BID | 10 mg, single dose | 2.08 (1.56 to 2.76) 3 | 3.04 (2.36 to 3.92) 3
Fostamatinib 100 mg BID | 20 mg, single dose | 1.96 (1.77 to 2.15) 3 | 1.88 (1.69 to 2.09) 3
Febuxostat 120 mg QD for 4 days | 10 mg, single dose | 1.9 (1.5 to 2.5) 3 | 2.1 (1.8 to 2.6) 3
Gemfibrozil 600 mg BID for 7 days | 80 mg | 1.9 to 3 | 2.2 to 3
Tafamidis 61 mg BID on Days 1 & 2, followed by QD on Days 3 to 9 | 10 mg | 1.97297 (1.68 to 2.31)3 | 1.86286 (1.59 to 2.16)3
Eltrombopag 75 mg QD, 5 days | 10 mg | 1.6 (1.4 to 1.7) 3 | 2 (1.8 to 2.3) 3
Darunavir 600 mg/ritonavir 100 mg BID, 7 days | 10 mg, QD for 7 days | 1.5 (1.0 to 2.1) 3 | 2.4 (1.6 to 3.6) 3
Tipranavir/ritonavir combination 500 mg/200 mg BID for 11 days | 10 mg | 1.4 (1.2 to 1.6) 3 | 2.2 (1.8 to 2.7) 3
Dronedarone 400 mg BID | 10 mg | 1.4 |
Itraconazole 200 mg QD, 5 days | 10 mg or 80 mg | 1.4 (1.2 to 1.6) 3 1.3 (1.1 to 1.4) 3 | 1.4 (1.2 to 1.5) 3 1.2 (0.9 to 1.4) 3
Ezetimibe 10 mg QD, 14 days | 10 mg, QD for 14 days | 1.2 (0.9 to 1.6) 3 | 1.2 (0.8 to 1.6) 3
Fosamprenavir/ritonavir 700 mg/100 mg BID for 7 days | 10 mg | 1.1 | 1.5
Fenofibrate 67 mg TID for 7 days | 10 mg | ↔ | 1.2 (1.1 to 1.3) 3
Rifampicin 450 mg QD, 7 days | 20 mg | ↔ |
Aluminum & magnesium hydroxide combination antacid Administered simultaneously Administered 2 hours apart | 40 mg 40 mg | 0.5 to(0.4 3to0.5) 0.8 (0.7 to 0.9) 3 | 0.5 3(0.4 to0.6) 0.8 (0.7 to 1.0) 3
Ketoconazole 200 mg BID for 7 days | 80 mg | 1.0 (0.8 to 1.2) 3 | 1.0 (0.7 to 1.3) 3
Fluconazole 200 mg QD for 11 days | 80 mg | 1.1 (1.0 to 1.3) 3 | 1.1 (0.9 to 1.4) 3
Erythromycin 500 mg QID for 7 days | 80 mg | 0.8 (0.7 to 0.9) 3 | 0.7 (0.5 to 0.9) 3
QD/OD= Once daily, BID= Twice daily, TID= Three times daily, QID= Four times daily
Table 9: Effect of Rosuvastatin Coadministration on Systemic Exposure to Other Drugs
2 unchanged lines
| Name and Dosage | Change in AUC | Change in Cmax
40 mg QD for 10 days | Warfarin 25 mg single dose | R- Warfarin 1.0 (1.0 to 1.1) 2 S-Warfarin 1.1 (1.0 to 1.1) 2 | R-Warfarin 1.0 (0.9 to 1.0) 2 S-Warfarin 1.0 (0.9 to 1.1) 2
40 mg QD for 12 days | Digoxin 0.5 mg single dose | 1.0 (0.9 to 1.2) 2 | 1.0 (0.9 to 1.2) 2
40 mg QD for 28 days | Oral Contraceptive (ethinyl estradiol 0.035 mg & norgestrel 0.180, 0.215 and 0.250 mg) QD for 21 Days | EE 1.3 (1.2 to 1.3) 2 NG 1.3 (1.3 to 1.4) 2 | EE 1.3 (1.2 to 1.3) 2 NG 1.2 (1.1 to 1.3) 2
EE = ethinyl estradiol, NG = norgestrel, QD= Once daily
2 unchanged lines

Clinical studies

Changed13 words added, 9 removed
1 unchanged line
Primary Prevention of CV Disease
In the Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) study, the effect of CRESTOR on the occurrence of major CV disease events was assessed in 17,802 males (≥50 years) and females (≥60 years) who had no clinically evident CV disease, LDL‑C levels <130 mg/dL and hsCRP levels ≥2 mg/L. The study population had an estimated baseline coronary heart disease risk of 11.6% over 10 years based on the Framingham risk criteria and included a high percentage of patients with additional risk factors such as hypertension (58%), low HDL‑C levels (23%), cigarette smoking (16%), or a family history of premature CHD (12%). Patients had a median baseline LDL‑C of 108 mg/dL and hsCRP of 4.3 mg/L. Patients were randomly assigned to placebo (n=89018,901) or CRESTOR 20 mg once daily (n=89018,901) and were followed for a mean duration of 2 years. The JUPITER study was stopped early by the Data Safety Monitoring Board due to meeting predefined stopping rules for efficacy in CRESTOR-treated subjects.
The primary end point was a composite end point consisting of the time-to-first occurrence of any of the following major CV events: CV death, nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina or an arterial revascularization procedure.
1 unchanged line
Figure 1. Time to First Occurrence of Major CV Events in JUPITER
The individual components of the primary end point are presented in Figure 32. CRESTOR significantly reduced the risk of nonfatal myocardial infarction, nonfatal stroke, and arterial revascularization procedures. There were no significant treatment differences between the CRESTOR and placebo groups for death due to CV causes or hospitalizations for unstable angina.
CRESTOR significantly reduced the risk of myocardial infarction (6 fatal events and 62 nonfatal events in placebo-treated subjects vs. 9 fatal events and 22 nonfatal events in CRESTOR-treated subjects) and the risk of stroke (6 fatal events and 58 nonfatal events in placebo-treated subjects vs. 3 fatal events and 30 nonfatal events in CRESTOR-treated subjects).
3 unchanged lines
Primary Hypercholesterolemia in Adults
CRESTOR reduces Total‑C, LDL‑C, ApoB, non‑HDL‑C, and TG, and increases HDL‑C, in adult patients with Hypercholesterolemiahypercholesterolemia and mixed dyslipidemia.
In a multicenter, double‑blind, placebo‑controlled study in patients with Hypercholesterolemiahypercholesterolemia, CRESTOR given as a single daily dose (5 to 40 mg) for 6 weeks significantly reduced Total‑C, LDL‑C, non‑HDL‑C, and ApoB, across the dose range (Table 10).
Table 10: Lipid-Modifying Effect of CRESTOR in Adult Patients with Hypercholesterolemia (Adjusted Mean % Change from Baseline at Week 6)
5 unchanged lines
CRESTOR 40 mg | 18 | -46 | -63 | -60 | -54 | -28 | 10
CRESTOR was compared with the statins (atorvastatin, simvastatin, and pravastatin) in a multicenter, open-label, dose‑ranging study of 2,240 patients with Hypercholesterolemiahypercholesterolemia or mixed dyslipidemia. After randomization, patients were treated for 6 weeks with a single daily dose of either CRESTOR, atorvastatin, simvastatin, or pravastatin (see Figure 3 and Table 11).
Figure 3. Percent LDL‑C Change by Dose of CRESTOR, Atorvastatin, Simvastatin, and Pravastatin at Week 6 in Adult Patients with Hypercholesterolemia or Mixed Dyslipidemia
Box plots are a representation of the 25th, 50th, and 75th percentile values, with whiskers representing the 10th and 90th percentile values. Mean baseline LDL‑C: 189 mg/dL.
Table 11: Percent Change in LDL-C by Dose of CRESTOR, Atorvastatin, Simvastatin, and Pravastatin From Baseline to Week 6 (LS Mean ) in Adult Patients with Hypercholesterolemia or Mixed Dyslipidemia (Sample Sizes Ranging from 156–167 Patients Per Group)
40 unchanged lines
Primary Dysbetalipoproteinemia in Adults
In a randomized, multicenter, double-blind crossovercross-over study, 32 adult patients ([27 with є2/є2 and 4 with apo E mutation [(Arg145Cys)] with primary dysbetalipoproteinemia entered a 6‑week dietary lead-in period on the NCEP Therapeutic Lifestyle Change (TLC) diet. Following dietary lead-in, patients were randomized to a sequence of treatments for 6 weeks each: rosuvastatin 10 mg followed by rosuvastatin 20 mg or rosuvastatin 20 mg followed by rosuvastatin 10 mg. CRESTOR reduced non-HDL‑C (primary end point) and circulating remnant lipoprotein levels. Results are shown in theTable table15, below.
Table 15: Lipid-Modifying Effects of CRESTOR 10 mg and 20 mg in Adult Patients with Primary Dysbetalipoproteinemia (Type III hyperlipoproteinemia) After Six Weeks by Median Percent Change (95% CI) from Baseline (N=32)
9 unchanged lines
Hypertriglyceridemia in Adults
In a double-blind, placebo-controlled study in adult patients with baseline TG levels from 273 to 817 mg/dL, CRESTOR given as a single daily dose (5 to 40 mg) over 6 weeks significantly reduced serum TG levels (see Table 16).
Table 16: Lipid-Modifying Effect of CRESTOR in Adult Patients with Primary Hypertriglyceridemia After Six Weeks by Median (Min, Max) Percent Change from Baseline to Week 6
6 unchanged lines

Patient counseling information

Changed2 words added, 1 removed
14 unchanged lines
Missed Doses
If a dose is missed, advise patients not to take an extra dose. Just resume the usual schedule [see Dosage and Administration (2.1)].
CRESTOR® is a trademarkregistered of the AstraZeneca group of companies.
© AstraZeneca 2026
4 unchanged lines

Patient information

Changed549 words added, 528 removed
PATIENT INFORMATION CRESTOR® (Kres-tor) (rosuvastatin) tablets, for oral use
Read this Patient Information carefully before you start taking CRESTOR and each time you get a refill. If you have any questions about CRESTOR, ask your healthcare provider. Only your healthcare provider can determine if CRESTOR is right for you.
What is CRESTOR? CRESTOR is a prescription medicine that contains a cholesterol-lowering medicine called rosuvastatin. •CRESTOR is used: ∘to reduce the risk of major adverse cardiovascular (CV) events, such as death from cardiovascular disease, heart attack, stroke, or the need for procedures to improve blood flow to the heart called arterial revascularization, in adults at increased risk for these events. ∘along with diet and exercise to lower the level of low-density lipoprotein (LDL-C) cholesterol or “bad” cholesterol: ▪∘in adults with primary hypercholesterolemia. ▪∘and slow the buildup of fatty deposits (plaque) in the walls of blood vessels in adults. ▪∘in adults and children 8 years of age and older with high blood cholesterol due to heterozygous familial hypercholesterolemia (HeFH) (an inherited condition that causes high levels of LDL-C). ▪∘in adults and children 7 years of age and older with homozygous familial hypercholesterolemia (HoFH) (an inherited condition that causes high levels of LDL-C). ∘along with diet for the treatment of adults with: ▪∘primary dysbetalipoproteinemia (an inherited condition that causes high levels of cholesterol and fat). ▪∘hypertriglyceridemia. It is not known if CRESTOR is safe and effective in children younger than 8 years of age with HeFH or children younger than 7 years of age with HoFH or in children with other types of hypercholesterolemias (other than HeFH or HoFH).
Do not take CRESTOR if you: •have liver problems. •are allergic to rosuvastatin or any of the ingredients in CRESTOR. See the end of this leaflet for a complete list of ingredients in CRESTOR.
Before you take CRESTOR, tell your healthcare provider about all of your medical conditions, including if you: •have unexplained muscle aches or weakness. •have or have had kidney problems. •have or have had liver problems. •drink more than 2 glasses of alcohol daily. •have thyroid problems. •are of Asian descent. •are pregnant or think you may be pregnant, or are planning to become pregnant. If you become pregnant while taking CRESTOR, call your healthcare provider right away to discuss your CRESTOR treatment. •are breastfeeding. CRESTOR can pass into your breast milk and may harm your baby. Talk to your healthcare provider about the best way to feed your baby if you take CRESTOR. Do not breastfeed while taking CRESTOR. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Tell your healthcare provider who prescribes CRESTOR if another healthcare provider increases the dose of another medicine you are taking. CRESTOR may affect the way other medicines work, and other medicines may affect how CRESTOR works.
Before you take CRESTOR, tell your healthcare provider about all of your medical conditions, including if you: •have unexplained muscle aches or weakness. •have or have had kidney problems. •have or have had liver problems. •drink more than 2 glasses of alcohol daily. •have thyroid problems. •are of Asian descent. •are pregnant or think you may be pregnant, or are planning to become pregnant. If you become pregnant while taking CRESTOR, call your healthcare provider right away to discuss your CRESTOR treatment. •are breastfeeding. CRESTOR can pass into your breast milk and may harm your baby. Talk to your healthcare provider about the best way to feed your baby if you take CRESTOR. Do not breastfeed while taking CRESTOR. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Tell your healthcare provider who prescribes CRESTOR if another healthcare provider increases the dose of another medicine you are taking. CRESTOR may affect the way other medicines work, and other medicines may affect how CRESTOR works. Especially tell your healthcare provider if you take: •coumarin anticoagulants (medicines that prevent blood clots, such as warfarin) •antacids (medicines you take for heartburn that contain aluminum and magnesium hydroxide Taking CRESTOR with certain medicines may increase the risk of muscle problems. Especially tell your healthcare provider if you take: •cyclosporine (a medicine for your immune system) •teriflunomide (a medicine used to treat relapsing remitting multiple sclerosis) •enasidenib (a medicine used to treat acute myeloid leukemia) •capmatinib (a medicine for the treatment of non-small cell lung cancer) •fostamatinib (a medicine used to treat low platelet counts) •febuxostat (a medicine used to treat and prevent high blood levels of uric acid) •gemfibrozil (a fibric acid medicine for lowering cholesterol) •tafamidis [used to treat cardiomyopathy (enlarged and thickened heart muscle)] •anti-viral medicines including certain HIV or hepatitis C virus drugs such as: ∘lopinavir, ritonavir, fosamprenavir, tipranavir, atazanavir, simeprevir ∘combination of ∘sofosbuvir/velpatasvir/voxilaprevir ∘dasabuvir/ombitasvir/paritaprevir/ritonavir ∘elbasvir/grazoprevir ∘sofosbuvir/velpatasvir ∘glecaprevir/pibrentasvir and ∘all other combinations with ledipasvir including ledipasvir/sofosbuvir •darolutamide (a medicine for the treatment of prostate cancer) •regorafenib (a medicine used to treat cancer of the colon and rectum) •fibric acid derivatives (such as fenofibrate) •ticagrelor (helps reduce the chance of a blood clot formation that can block a blood vessel) •niacin or nicotinic acid •colchicine (a medicine used to treat gout) •belumosudil (used to treat chronic graft-versus-host disease) •momelotinib (used to treat myelofibrosis, a rare form of blood cancer) •vadadustat (medicine used to treat anemia caused by chronic kidney disease (CKD) in adults on dialysis for at least 3 months) Ask your healthcare provider or pharmacist for a list of these medicines if you are not sure. Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get new medicine.
Especially tell your healthcare provider if you take: •coumarin anticoagulants (medicines that prevent blood clots, such as warfarin) •antacids (medicines you take for heartburn that contain aluminum and magnesium hydroxide Taking CRESTOR with certain medicines may increase the risk of muscle problems. Especially tell your healthcare provider if you take: •cyclosporine (a medicine for your immune system) •teriflunomide (a medicine used to treat relapsing remitting multiple sclerosis) •enasidenib (a medicine used to treat acute myeloid leukemia) •capmatinib (a medicine for the treatment of non-small cell lung cancer) •fostamatinib (a medicine used to treat low platelet counts) •febuxostat (a medicine used to treat and prevent high blood levels of uric acid) •gemfibrozil (a fibric acid medicine for lowering cholesterol) •tafamidis [used to treat cardiomyopathy (enlarged and thickened heart muscle)] •anti-viral medicines including certain HIV or hepatitis C virus drugs such as: ∘lopinavir, ritonavir, fosamprenavir, tipranavir, atazanavir, simeprevir ∘combination of ▪sofosbuvir/velpatasvir/voxilaprevir ▪dasabuvir/ombitasvir/paritaprevir/ritonavir ▪elbasvir/grazoprevir ▪sofosbuvir/velpatasvir ▪glecaprevir/pibrentasvir and ∘all other combinations with ledipasvir including ledipasvir/sofosbuvir •darolutamide (a medicine for the treatment of prostate cancer) •regorafenib (a medicine used to treat cancer of the colon and rectum) •fibric acid derivatives (such as fenofibrate) •ticagrelor (helps reduce the chance of a blood clot formation that can block a blood vessel) •niacin or nicotinic acid •colchicine (a medicine used to treat gout) •belumosudil (used to treat chronic graft-versus-host disease) •momelotinib (used to treat myelofibrosis, a rare form of blood cancer) Ask your healthcare provider or pharmacist for a list of these medicines if you are not sure. Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get new medicine.
How should I take CRESTOR? •Take CRESTOR exactly as your healthcare provider tells you to take it. •Take CRESTOR, by mouth, 1 time each day, with or without food. Swallow the tablet whole. •CRESTOR can be taken at any time of day, with or without food. • Do not change your dose or stop CRESTOR without talking to your healthcare provider, even if you are feeling well. •Your healthcare provider may do blood tests to check your cholesterol levels before and during your treatment with CRESTOR. Your healthcare provider may change your dose of CRESTOR if needed. •While taking CRESTOR, continue to follow your cholesterol-lowering diet and to exercise as your healthcare provider told you to. •If you take a medicine called an antacid that contains a combination of aluminum and magnesium hydroxide, take CRESTOR at least 2 hours before you take the antacid. •If you miss a dose of CRESTOR, take your next dose at your normal scheduled time. Do not take an extra dose of CRESTOR. •In case of an overdose, get medical help or contact a live Poison Center expert right away at 1-800-222-1222. Advice is also available online at poisonhelp.org.
What are the possible side effects of CRESTOR? CRESTOR may cause serious side effects, including: • Muscle pain, tenderness and weakness (myopathy). Muscle problems, including muscle breakdown, can be serious in some people and rarely cause kidney damage that can lead to death. Tell your healthcare provider right away if: ∘you have unexplained muscle pain, tenderness, or weakness, especially if you have a fever or feel more tired than usual, while you take CRESTOR. ∘you have muscle problems that do not go away even after your healthcare provider has told you to stop taking CRESTOR. Your healthcare provider may do further tests to diagnose the cause of your muscle problems. Your chances of getting muscle problems are higher if you: ∘are taking certain other medicines while you take CRESTOR (see “Especially tell your healthcare provider if you take”) ∘are 65 years of age or older ∘are of Asian descent ∘have thyroid problems (hypothyroidism) that are not controlled ∘have kidney problems ∘are taking higher doses of CRESTOR • Liver problems. Your healthcare provider may do blood tests to check your liver before you start taking CRESTOR and if you have symptoms of liver problems while you take CRESTOR. Call your healthcare provider right away if you have any of the following symptoms of liver problems: ∘feel unusually tired or weak ∘loss of appetite ∘upper belly pain ∘dark urine ∘yellowing of your skin or the whites of your eyes • Protein and blood in the urine. CRESTOR may cause you to have protein and blood in your urine. If you develop protein or blood in your urine, your healthcare provider may decrease your dose of CRESTOR. • Increase in blood sugar (glucose) levels. CRESTOR may cause an increase in your blood sugar levels. The most common side effects may include headache, nausea, muscle aches and pains, weakness, and constipation. Tell your healthcare provider if you have any side effect that bothers you or that does not go away. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
The most common side effects may include headache, nausea, muscle aches and pains, weakness, and constipation. Tell your healthcare provider if you have any side effect that bothers you or that does not go away. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store CRESTOR? •Store CRESTOR at room temperature, between 68°F to 77°F (20°C to 25°C) and in a dry place. Keep CRESTOR and all medicines out of the reach of children.
1 unchanged line
What are the Ingredients in CRESTOR? Active Ingredient: rosuvastatin as rosuvastatin calcium Inactive Ingredients: crospovidone NF, hypromellose NF, lactose monohydrate NF, magnesium stearate NF, microcrystalline cellulose NF, red ferric oxide NF, titanium dioxide USP, triacetin NF, tribasic calcium phosphate NF and yellow ferric oxide.
CRESTOR® is a trademarkregistered of the AstraZeneca group of companies. © AstraZeneca 2026 Licensed from SHIONOGI & CO., LTD., Osaka, Japan Distributed by: AstraZeneca Pharmaceuticals LP Wilmington, DE 19850 For more information, go to the CRESTOR website at www.crestor.com or call 1-800-CRESTOR
This Patient Information has been approved by the U.S. Food and Drug Administration Revised 0409/2026

Unchanged: Dosage forms and strengths, Contraindications, Overdosage, Description, Nonclinical toxicology, How supplied, Package/Label Display Panel – 5 mg, Package/Label Display Panel – 10 mg, Package/Label Display Panel – 20 mg, Package/Label Display Panel – 40 mg.

Every version

12 versions of set 325a5d0e-9a72-4015-9fcd-1655fb504cee, newest first.
VersionPublished on DailyMedCompareSPL file
19Sep 30, 2026Shown belowDownload .zip
14May 13, 2026With version 13Download .zip
13Dec 19, 2025With version 12Download .zip
12Aug 7, 2024With version 11Download .zip
11Apr 15, 2024With version 8Download .zip
8Feb 28, 2024With version 7Download .zip
7Aug 4, 2023With version 6Download .zip
6Mar 23, 2023With version 5Download .zip
5Jan 23, 2023With version 4Download .zip
4May 9, 2022With version 3Download .zip
3Jan 31, 2022With version 2Download .zip
2Jan 24, 2022First versionDownload .zip

Read an SPL file

Open an SPL label file

Drop a Structured Product Labeling .xml file, or the .zip DailyMed downloads, to read it as a label. It is read in this browser tab and not uploaded.

Read in this browser tab; nothing is uploaded.

Versions and label text from DailyMed's SPL web services; a version's text is read from its SPL file, so it matches what DailyMed shows. Recent safety-related changes from FDA's Safety-related Labeling Changes database, which covers NDAs and CDER biologics, not generics. Lists refresh daily. DailyMed, National Library of Medicine

About label change history

How to read a comparison

Sections that changed come first, in the order a reviewer reads a label: boxed warning, recent major changes, indications, dosage, contraindications, warnings and precautions, adverse reactions, then the rest. Each shows the changed lines with one unchanged line either side; longer unchanged stretches are folded into a count. Table rows read left to right with cells separated by a bar.

The comparison covers the label text. Images, product data (NDC codes, ingredients, packaging) and formatting are not compared.

Which label is shown

A drug can have several labels: one per brand-name application (Ozempic, Wegovy and Rybelsus are three), and copies from repackagers. For each NDA or BLA the page takes the DailyMed set with the most versions, which is the application holder's. Generic labels are left out; they follow the brand's label.

Frequently asked questions

Where do the versions come from?
DailyMed, the National Library of Medicine's library of labels in Structured Product Labeling (SPL) format. Each time a company submits a revised label, DailyMed publishes it as a new version of the same set and keeps the old ones.
Is a new version a new FDA approval?
Not always. Companies also submit new versions for changes that need no FDA approval first, such as a new address, a new package size or a corrected typo. Safety changes FDA approved are listed in its Safety-related Labeling Changes database, linked below.
Why does the published date differ from the label's revised date?
The published date is when DailyMed posted the version. The label's own revised date, at the end of the highlights, is when the company revised the text, usually a few days to weeks earlier.
How is the comparison made?
Each section is matched by its standard LOINC code, then split into headings, paragraphs, list items and table rows. Lines are aligned with a longest-common-subsequence diff; a removed and an added line that share at least half their words are shown as one edited line with the changed words marked. Curly quotes, dash styles and spacing are ignored.
Is my SPL file uploaded?
No. A file you drop on this page is read in your browser tab and never sent to Arca.
Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.